Sign in
Taking people in United StatesPhase 2

Laser heat therapy or surgery, then more radiation, for returning brain metastases

Tests laser heat therapy or surgery plus radiation in adults with recurrent brain metastases.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Status
Recruiting
Phase
Phase 2
People taking part
155 people, planned
Started
1 Jan 2026
Expected to end
30 Dec 2028
Type of study
Interventional, 3 groups
Treatments tested
  • Surgery
  • LITT
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose brain metastases (cancer spread to the brain from a solid tumor) seem to be growing again after earlier stereotactic radiosurgery (SRS), a focused radiation treatment.

Age
18 years and older.
Sex
All sexes.
Disease stage
Brain metastasis from a solid tumor that seems to be growing again on scans. At least one lesion of 5 mm or more on MRI. Active tumor found in tissue taken during surgery or LITT for this lesion. Karnofsky performance status of 60 or higher. No sign on scans of cancer spread to the lining of the brain (leptomeningeal disease).
Earlier treatment
The lesion must have had stereotactic radiosurgery at least 3 months before joining. The treating doctors must agree that the person can have a second radiosurgery (SRS2).

Main reasons for not taking part

  • Brain metastases from blood cancers
  • Pregnancy
  • Not able to safely have an MRI scan
  • Mental illness or social situation that would make it hard to follow the study rules
  • Other cancer that would affect the safety or results of the study treatment

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Ability to understand and the willingness to sign a written informed consent document
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study
  • Karnofsky performance status ≥ 60
  • Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan
  • Have active tumor on pathology from surgery/LITT for this lesion
  • Able to safely undergo MRI imaging
  • Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus
  • Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

Who cannot take part

  • Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following:
  • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)
  • Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • History of hysterectomy or bilateral salpingo-oophorectomy
  • History of bilateral tubal ligation or another surgical sterilization procedure
  • Postmenopausal (no menses in greater than or equal to 12 consecutive months)

This trial is currently available in United States.

  • The University of Texas M. D. Anderson Cancer CenterHouston, United StatesContact: Subha Perni, MDTaking people

About the trial

What the trial wants to find out

standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).

The 3 groups in the trial

  • Eligible for surgery or LITT-SurveillanceTreatment being tested

    Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.

    Treatment: Surgery and LITT

  • Eligible for surgery or LITT-SRS2Treatment being tested

    Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.

    Treatment: Surgery and LITT

  • Ineligible for surgery or LITT-SRS2Treatment being tested

    Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.

    Treatment: Surgery and LITT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
Plain-language title
Laser heat therapy or surgery, then more radiation, for returning brain metastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
18 September 2026